VTE Prophylaxis in Orthopaedics in 2026: Aspirin, LMWH, DOACs, and Trauma-Specific Decisions

VTE prophylaxis is a classic orthopaedic trap because it invites oversimplification. One camp wants aspirin for almost everyone. Another camp trusts low-molecular-weight heparin by default. A third treats every patient as a unique coagulation puzzle and risks paralysis by nuance. The right answer is more disciplined: the optimal prophylaxis depends on the operation, the injury, the patient’s thrombosis risk, and the bleeding cost of getting it wrong.

Fast Takeaways

• Arthroplasty and trauma should not be treated as the same VTE prophylaxis problem.
• The PREVENT CLOT trial changed trauma practice by showing aspirin was noninferior to LMWH for mortality after many operative extremity and pelvic fractures.
• That does not mean aspirin is universally best. DVT nuance, bleeding risk, mobility, and patient factors still matter.
• Low-risk primary arthroplasty patients may reasonably receive aspirin-based protocols in many practices.
• Higher-risk patients still justify more potent chemoprophylaxis in many centres.

Why This Matters in 2026

The field changed meaningfully after PREVENT CLOT. Before that trial, many trauma services defaulted to LMWH because it had the strongest tradition and guideline support. After it, the conversation became more nuanced. Aspirin could no longer be dismissed as automatically inferior for many fracture patients.

At the same time, arthroplasty practice has remained heterogeneous. Some surgeons prefer aspirin in standard-risk primary joint replacement. Others escalate quickly to LMWH or a DOAC when risk accumulates. The correct lesson is not that one side has won. The lesson is that orthopaedic thromboprophylaxis is now more explicitly risk-stratified.

The Core Decision Points

1. Separate trauma from elective arthroplasty

The evidence base and clinical context are different. In trauma, patients may be younger, multiply injured, temporarily immobile, and variably bleeding. In elective arthroplasty, the pathway is more controlled and risk stratification can be cleaner.

That is why one unified statement such as “aspirin is enough” or “LMWH is mandatory” usually sounds too blunt.

2. Understand what PREVENT CLOT did and did not show

PREVENT CLOT showed that, in a large fracture population, aspirin was noninferior to LMWH for preventing death and was associated with low overall rates of DVT and PE. That is highly practice-changing.

But trainees should remember three caveats:

• the result is not identical to saying aspirin was superior for every thrombotic endpoint
• the enrolled population does not erase the need for individual risk assessment
• the trial informs, but does not completely settle, all trauma subgroups

3. Use risk stratification honestly in arthroplasty

For many routine primary hip and knee arthroplasty patients, aspirin-based prophylaxis is accepted and widely used. The conversation changes when the patient has:

• prior VTE
• active cancer
• marked obesity
• prolonged immobility
• thrombophilia
• major medical complexity

In these patients, many surgeons and centres still favour LMWH or a DOAC depending on bleeding profile and pathway design.

4. Do not forget the system around the drug

The 2023 Australian Hip Fracture Clinical Care Standard reminds clinicians to assess VTE risk as part of orthogeriatric care. That is a useful mindset across orthopaedics. Prophylaxis is safest when it sits inside a pathway, not when it relies on memory or habit.

Common Pitfalls

Treating PREVENT CLOT as permission to stop thinking

The trial supports aspirin in many fracture patients. It does not mean the patient with prior PE, major cancer burden, and prolonged recumbency should be managed as though nothing else matters.

Ignoring bleeding and wound risk

The safest anticoagulant on paper is not always the safest choice in a fresh wound with major bleeding concerns.

Forgetting duration and discharge planning

A sensible inpatient plan can fail if the patient leaves hospital confused about adherence, mobility, and warning symptoms.

Using drug choice as a substitute for mobilisation

Chemoprophylaxis cannot compensate fully for prolonged, preventable immobility.

Exam and Practice Pearls

• In a viva, say early that prophylaxis choice differs between trauma and elective arthroplasty.
• Mention venous thromboembolism and thromboprophylaxis as broader frameworks, not isolated prescriptions.
• If asked about hip fracture care, refer to orthogeriatric review, early surgery, and risk-based prophylaxis rather than drug dogma alone.
• If asked whether aspirin is acceptable after fracture surgery, the modern answer is yes in many patients, but within an appropriate risk framework.

References

1. O'Toole RV, O'Hara NN, Dodd AC, et al. Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture. New England Journal of Medicine. 2023.
2. Aspirin versus low-molecular-weight heparin for thromboprophylaxis after orthopaedic surgery: a systematic review and meta-analysis. 2024.
3. The efficacy of aspirin versus LMWH for VTE prophylaxis after knee and hip arthroplasty. 2024.
4. Arthroplasty Society of Australia guidelines for VTE prophylaxis for hip and knee arthroplasty.
5. Information for clinicians - Hip Fracture Clinical Care Standard. Australian Commission on Safety and Quality in Health Care.